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Abstract
BACKGROUND: The number of patients with diabetes mellitus (DM) is progressively increasing all over the world. 
Over the past three decades, the global burden of diabetes has increased from 30 million in 1985 to 382 million in 
2015, and current trends indicate that the prevalence of diabetes grows progressively. The phenomenon of insulin 
resistance established in the majority of type 2 DM (T2DM) patients. T2DM is associated with β-cell deficiency, α-cell 
resistance to insulin, and reduced effects of incretin. However, the role of insulin and glucagon in the process of 
cardiovascular complications in diabetic patients is a matter of debate.
AIM: Our study aims to estimate insulin resistance and the contrainsular response in patients with T2DM and acute 
coronary syndrome (ACS).
METHODS: The 104 T2DM patients aged 18–70 years participated in the observational study carried out in the 
Karaganda regional cardiosurgery hospital and ambulatory. The first group included 37 patients hospitalized for ACS 
in the first 24 h of admission. The second group included 67 patients without ACS. Determination of insulin resistance 
and contrainsular response was provided using a multiplex immunological assay with XMap technology on Bioplex 3D.
RESULTS: During the research, we have discovered a decreased level of glucagon and increased homeostasis 
model assessment of insulin resistance (HOMA-IR) in patients with T2DM diabetes and ACS. Evaluation of traditional 
correlation interactions of HOMA-IR and indicators of carbohydrate metabolism showed a positive correlation with 
fasting plasma glucose in both study groups (Group 1: R = 0.47, p = 0.003; Group 2: R = 0.41, p = 0.024). Glucagon-
like peptide (GLP)-1 has a weak positive correlation with HOMA-IR only in the first group (R = 0.32, p = 0.006). 
Increased insulin resistance was associated with high GLP-1 levels and low glucagon. The logistic regression model 
established that an increased HOMA-IR index rises the chance of ACS by 10.6% (OR = 1.106 [95% CI 1.105–1.206], 
p = 0,021). The logistic regression model, reflecting the relation between glucagon and ACS, shows that increased 
glucagon reduces the ACS odds (OR = 0.989 [95% CI 0.979–0.999], p = 0.026). The adjusted regression model 
showed no significant influence of early presented factors on the probability of ACS.
CONCLUSION: There is a trend toward elevated HOMA-IR insulin resistance index and decreased level of glucagon 
in diabetic patients with ACS.
Introduction
About 32.2% of all patients with type 2 diabetes 
mellitus (T2DM) around the world have cardiovascular 
diseases. Coronary artery disease and ischemic stroke 
cause approximately half of all deaths among people 
with diabetes [1].
The connection between T2DM and 
cardiovascular disease is undiscussable. Diabetes 
is considered one of the major independent 
cardiovascular risk factors, independent of additional 
confounders such as age, arterial hypertension, 
smoking, hypercholesterolemia, and left ventricular 
hypertrophy [2]. The mortality rate in patients with 
T2DM from macrovascular complications allows the 
researchers to think about its decisive importance for 
the further prognosis of the disease [3].
The fundamental pathogenetic role of 
hyperinsulinism in T2DM is established in many 
longitudinal studies [4], [5]. Insulin resistance criteria 
homeostasis model assessment of insulin resistance 
(HOMA-IR) associated with high cardiovascular 
risk have been shown in several studies [6], [8]. 
Increased insulin concentration elevates the risk of 
adverse cardiovascular outcomes in adult patients 
after coronary revascularization [9], [10]. However, 
the diagnostic significance of the quantitative assay of 
insulin resistance was insufficiently studied in T2DM 
and adverse cardiovascular events.
The simplest criteria of insulin resistance are 
HOMA-IR [11], [12], [13]. The association of HOMA-IR 
with a high cardiovascular risk is established in 
some studies of patients without diabetes [14], [15]. 
Nevertheless, the crosslink of HOMA-IR with the level of 
cardiovascular risk among patients with established type 
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2 diabetes is controversial. In the Verona Diabetes Study, 
the Veteran’s Affairs Diabetes Trial, and the study of high-
density lipoprotein (HDL) in patients with percutaneous 
coronary intervention, HOMA-IR is associated with an 
increased risk of cardiovascular events [16], [17]. The 
opposite trend with no link between HOMA-IR and 
adverse cardiovascular events is described in a study of 
cardiovascular risks in the UK [18].
At the same time, biomarkers of the 
contrainsular response are considered valuable 
pathogenetic biomarkers of T2DM. One of the important 
agents of this group is glucagon. In addition to the 
contrainsular action, glucagon plays a significant role 
in maintaining heart and kidneys function. Moreover, 
in the medical practice of the previous years, glucagon 
has been therapeutically used to treat heart failure.
In physiological conditions, glucagon secretion 
is regulated by insulin and somatostatin, as the main 
paracrine/endocrine inhibitors. Many other agents such 
as glucose, incretins (glucagon-like peptide (GLP)-
1, amylin, leptin, fatty acids, ketone bodies, glucose-
dependent insulinotropic peptide (GIP), amino acids 
as l-arginine, and leucine could regulate its secretion. 
Meyer et al. demonstrated that GLP-2 can also stimulate 
glucagon secretion [19], [20].
Pathogenetic molecular changes in T2DM 
could be schematically characterized by β-cell 
deficiency, α-cell resistance to insulin, and reduced 
effects of incretins. Β-cell deficiency develops gradually, 
due to partial loss of their mass and dysfunction under 
the influence of genetic background of glucotoxicity 
and lipotoxicity and the advanced products of 
enhanced glycation [21]. Presumably, hyperglycemia 
induces long-term, self-sustaining processes in the 
vessels which are associated with oxidative stress 
and chronic inflammation. They play an important role 
in the “metabolic memory” phenomenon and insulin 
resistance process, as well as in the diabetic macro and 
microvascular complications development [22], [23].
The aim of the study was to evaluate the 
indicators of insulin resistance including insulin and 
C-peptide, and contrainsular response including 
glucagon and GLP 1, GIP in patients with type 2 
diabetes and cardiovascular events (acute coronary 
syndrome [ACS]).
Materials and Methods
Study subjects
We conducted an observational cohort study of 
104 patients with type 2 diabetes, aged 18–70 years old. 
The inclusion criteria were preexisting T2DM, either with 
the ACS at the first 24 h from the initial symptoms of a 
cardiovascular event or diabetic patients with cardiovascular 
risk factors: Arterial hypertension, abdominal obesity, and 
dyslipidemia without cardiovascular events in medical 
history. Exclusion criteria were pregnancy, severe mental, 
and oncological diseases.
The sample size was calculated by the Kelsey 
method using EPI info software for unmatched cohort 
studies with a two-sided confidence level of 95%, power 
is 80%, the ratio of unexposed to exposed cases is 2. 
The presence of outcomes (ACS in diabetic patients) 
was taken from the previous studies. The minimum 
exposed cases are 35 and unexposed is 69. The time 
of data collection was from October 2017 to June 2018 
at Karaganda regional cardiosurgery hospital and 
different ambulatories of Karaganda city, Kazakhstan.
Data collection
The study inclusion process was started with 
the procedure of gaining signed informed consent. In 
both study groups, medical history, clinical examination, 
anthropometry, arterial blood pressure, plasma glucose, 
lipid profile, and glycosylated hemoglobin (HbA1c) were 
collected. Physical examination included blood pressure 
measurement according to principles of the World Health 
Organization using a mechanical tonometer (Microlife 
BP AG1-10) on both hands with at least 10 min rest 
preliminary period [24]. The lowest of three consecutive 
measurements were taken for future calculations. 
Bodyweight and height were measured using a digital 
stadiometer with scales (TBEC RS-232). The body mass 
index (BMI) was calculated as body weight divided on a 
square of height in meters (kg/m2). Waist circumference 
(WC) was measured with non-elastic measuring tape on 
the thinnest part of the corpus.
Blood samples
Blood glucose measurement was provided using a 
glucose meter (Accu-Chek Active). The diagnosis of T2DM 
was established on the HbA1c level greater or equal 6.5% 
by the 1997 American Diabetes Association [25]. HbA1c 
concentration was established with the NycoCard test 
system from venous blood by reflectometry method using 
the NycoCard Reader II blood analyzer. All the parameters 
of lipid profile (total cholesterol [TC], low-density lipoprotein 
cholesterol [LDL cholesterol], HDL cholesterol [HDL 
cholesterol], and triglycerides [TGs]) were estimated 
in plasma by the method of selective precipitation with 
phosphotungstate and magnesium.
Plasma samples were stored at −70°C for not 
more than 3 months. We used method of the magnetic 
bead-based multiplex immunoassay using XMap 
technology for detecting insulin, C-peptide, glucagon, 
GLP-1, and GIP. The standard Bio-Plex Pro Human 
Diabetes, 10-Plex Panel kit was used to determine the 
concentration of listed metabolites in accordance with 
“Overnight protocol” by the instruction of the manufacturer. 
The protocol consisted of three steps. The first step was 
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the incubation of unknown, standard, and control samples 
with magnetic beads loaded with primary antibodies. The 
second step was the revelation using detecting antibodies 
and Streptavidin Phycoerythrin Conjugated. The third 
step of the protocol was fluorescence registration using 
Bioplex 3D equipment (Luminex software). All detected 
analytes with minimum detectable concentration have a 
coefficient of variation <10%.
Statistical analysis
We conducted the Kolmogorov–Smirnov 
test for verification of the normal distribution of data. 
The description of the quantitative data was carried 
out by the median and quartiles. The Mann–Whitney 
U-test or t was used to compare two independent 
parameters. The association of insulin resistance 
and contrainsular response was evaluated using the 
Spearman correlation coefficient and the binary logistic 
regression model. We use age, gender, treatment, 
social, and demographic characteristics for adjusted 
risk calculation. Statistical analysis was provided on 
IBM SPSS Statistics software, ver. 22.0. Results were 
considered statistically significant at p < 0.05.
Results
The participants’ baseline characteristics are 
presented in Table 1. The first group included 37 patients 
with T2DM and ACS, the second group comprised 67 
T2DM patients without ACS. In the first group, there is bias 
to male patients. The median age of patients in the first 
group was higher than the second. Significant differences 
are also found among patients by the educational level and 
marital status. The number of participants with graduate 
education is lower in the ACS group in comparison with 
participants without ACS. Comparison of marital status 
same as the duration of T2DM shows the almost equal 
percentage of participants in both groups.
Table 1: Baseline characteristics participants (n = 104)
Parameter 1st group (T2DM with 
ACS), n = 37
2nd group (T2DM 
without ACS) n = 67
р
Age, years 59.00 (54.00, 63.25) 49.50 (37.50, 56.75) 0.001
Male (42) 24 (64.8) 16 (23.9) 0.012
Female (62) 13 (35.2) 51 (76.1) 0.017
Middle school course 23 (62.2) 39 (58.2) 0.112
Graduate education 14 (37.8) 28 (41.8) 0.019
Single 14 (37.8) 15 (22.4) 0.889
Married 23 (62.2) 52 (77.6) 0.013
Duration of T2DM, years 5.00 (2.00, 15.25) 6.00 (3.00, 12.50) 0.960
Categorical variables are present as n (%); non-parametric distributed continuous variables as median (first 
quartile, third quartile). Mann–Whitney U-test was used for non-parametric continuous variables, χ2 test 
was used for categorical variables
Clinical and laboratory findings are presented 
in Table 2. In the group of patients with T2DM and 
ACS, compared with the group without ACS, there is 
a significant increase of traditional cardiovascular risk 
factors such as systolic blood pressure, diastolic blood 
pressure, and increased LDL level.
Table 2: Clinical and laboratory findings
BMI, kg/m2 30.76 (25.10, 34.37) 28.43 (25.08, 32.65) 0.193
WC, cm 96.00 (92.00, 103.00) 91.00 (80.00, 107.25) 0.286
SBP, mm of mercury 130.00 (120.00, 150.00) 120,00 (110.00, 130.00) 0.027
DBP, mm of mercury 80.00 (80.00, 90.00) 80.00 (70.00, 80.00) 0.008
LDL, mmol/l 0.92 (0.75, 1.19) 1.10 (0.87, 1.33) 0.041
HDL, mmol/l 4.51 (3.20, 5.27) 3.96 (3.12, 4.40) 0.176
TG, mmol/l 1.39 (0.77, 1.73) 1.22 (0.68, 1.85) 0.550
C-peptide, ng/ml 1430.03 (831.63, 2641.85) 1098.35 (754.22, 2436.73) 0.715
GLP-1, ng/ml 113.47 (70.42, 141.91) 82.95 (54.70, 134.75) 0.185
GIP, ng/ml 252.26 (130.92, 670.85) 233.50 (126.84, 398.20) 0.226
Glucagon, ng/ml 57.79 (51.11, 150.26) 1377.77 (418.10, 6078.86) <0.001
Insulin, mU/L 14.96 (5.87, 26.27) 7.29 (4.20, 20,59) 0.077
HOMA-IR 4.58 (1.62, 9.55) 1.95 (0.876, 6,56) 0.035
T2DM treatment
Metformin 23 (62.2) 43 (64.2) 0.786
Sulfonylurea 9 (24.3) 13 (19.4) 0.634
IDPP4 1 (2.9) 4 (5.9) 0.606
Insulin 4 (10.8) 7 (11.9) 0.064
GIP: Gastric inhibitory polypeptide, BMI: Body mass index, WC: Waist circumference, SBP: Systolic blood 
pressure, DBP: Diastolic blood pressure.
Estimation of insulin resistance provided by 
HOMA-IR calculation revealed an increased level 
of this parameter in patients with T2DM and ACS. A 
similar trend was noted for glucagon levels. There are 
no differences found by the middle school course, BMI, 
WC, plasma glucose level, HbA1c, TC, LDL cholesterol, 
TG, C peptide, GIP, and insulin.
Patients received one of three oral 
hypoglycemic agents: Metformin, sulfonylurea, DPP4 
inhibitors (dipeptidyl peptidase-4 inhibitors), or insulin. 
No significant differences were found in the number of 
patients by prescribed therapy.
Assessment of correlation (Table 3) between 
the level of insulin resistance and anthropometric 
indicators revealed a middle positive correlation 
between HOMA-IR and BMI (R = 0.65, p = < 0.001). 
Similar upward trend revealed for the patients from 
the second group (R = 0.47, p = 0.010). A significant 
positive correlation of HOMA-IR with WC was noted 
only for a group of patients with T2DM and ACS. In 
both studied groups, there is a significant correlation 
between HOMA-IR and weight. Stronger interaction 
was in patients with T2DM without ACS (first group: 
R = 0.32, p = 0.006; second group: R = 0.62, p ≤ 0.001). 
An assessment of traditional correlation interactions 
of HOMA-IR and carbohydrate indicators showed 
an average positive correlation with fasting plasma 
glucose in both groups studied (the first group: R = 0.47, 
p = 0.003; the second group: R = 0.41, p = 0.024). 
GLP-1 responsible for the contrainsular response 
has a weak positive correlation with HOMA-IR only in 
the group of patients with T2DM and ACS (R = 0.32, 
p = 0.006). Increased insulin resistance is associated 
with an increased GLP-1 level and a decreased 
glucagon level.
Table 3: Correlation coefficients of HOMA-IR
Parameter 1st group (T2DM with ACS) 2nd group (T2DM without ACS)
R Р R Р
BMI 0.65 <0.001 0.47 0.010
Plasma glucose 0.47 0.003 0.41 0.024
WC −0.18 0.474 0.49 0.002
Weight 0.32 0.036 0.62 0.001
HbA1c 0.16 0.409 −0.08 0.661
C-peptide 0.01 0.964 0.06 0.716
GLP-1 0.294 0.007 0.13 0.506
Glucagon −0.09 0.653 0.11 0.506
WC: Waist circumference
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A binary logistic regression model that 
assesses the effect of insulin resistance (Table 4) 
revealed that an increased HOMA-IR index significantly 
enhances the chance of ACS by 10.6%, OR = 1.106 
(95% CI 1.105–1.206).
Table  4:  Model  of  binary  logistic  regression  for  HOMA-IR, 
glucagon,  and  adjusted  regression  model  for  HOMA-IR  and 
glucagon
Parameter Significance Odds ratio 95%CI for exp (B)
Lower Upper
Model 1
HOMA-IR 0.021 1.106 1.015 1.206
Model 2
Glucagon 0.026 0.989 0.979 0.999
Model 3 Model of binary logistic regression for HOMA-IR and glucagon adjusted for age, 
gender, marital status, and treatment
Glucagon 0.539 1.000 1.000 1.001
Insulin 0.614 0.999 0.997 1.002
HOMA-IR 0.660 1.040 0.874 1.238
The binary logistic regression model, 
representing the relationship of the glucagon level 
with the ACS odds, shows that increased glucagon 
concentration significantly reduces the chance of the 
ACS onset (OR = 0.989 [95% CI 0.979–0.999]).
The model of binary logistic regression 
adjusted for age, gender, education, marital status, 
and treatment does not reveal any significant impact 
of HOMA-IR and glucagon on the probability of ACS. 
However, such cofounders as male gender (OR = 52,779 
[95% CI 4.687–94.391]) and age (OR = 1.193 [95% CI 
1.036–1.375]) increase the ACS odds. The graduate 
education (OR = 0.012 [95% CI 0.000–0.324]) reduces 
the probability of ACS.
Discussion
We have obtained the unambiguous data reflect 
the negative effect of insulin resistance on cardiovascular 
safety in our study. The level of HOMA-IR in patients with 
DM was higher during the ACS period than in similar 
patients with diabetes without ACS. It is also associated 
with an increased chance of an adverse cardiovascular 
event. At the same time, an increased level of HOMA-IR 
and decreased level of glucagon established an impact 
on the odds ratio of ACS [26]. The obtained results can 
be explained by the studies of α-cells insulin resistance 
in T2DM. Α-cells can be resistant to the inhibitory action 
of insulin or other β-cell secretory products, such as zinc 
or γ-aminobutyric acid [27].
In our research, glucagon shows diagnostic 
value in ACS prognosis. Moreover, glucagon shows 
greater significance than HOMA-IR in constructing a 
combined prognostic model of logistic regression. The 
impact of glucagon can be explained by the modern 
conception of DM pathogenesis. Diabetes is characterized 
by fasting hyperglycemia and impaired glucose-induced 
suppression of glucagon in the postprandial state. This 
condition arises mainly due to β-cells apoptosis and bias 
of the β/α-cells ratio to α-cells. The condition contributes to 
decreased insulin to glucagon ratio. Furthermore, β-cells 
can dedifferentiate to pluripotent predecessor cells that 
can release glucagon and somatostatin, thereby further 
reducing the insulin/glucagon ratio [28]. In this context, 
it seems clear that glucagon, with a certain reserve of its 
secretion, plays a major role in the reduction of metabolic 
effects of exceeding insulin secretion [29]. Besides, T2DM 
is characterized by a reduced effect of incretins, which 
progresses with the duration of the disease. Although 
the effects of GLP-1 are relatively preserved, prolonged 
hyperglycemia is capable of gradually suppressing the 
contrainsular response, creating a vicious cycle [30], [31].
The results obtained in our study did not match 
the concept that higher glucose level leads to the 
increased probability of ACS. According to such iconic 
studies as UKPDS and VADT, the glucose reduction 
is associated with a lower number of cardiovascular 
events and mortality in type 2 diabetes [32], [33], [34]. 
The data from these studies suggest that the glucose-
lowering conception that predominates in modern 
diabetology required achieving the target HbA1c level 
to reduce the risk of diabetic complications.
The number of patients who reached the 
target level of HbA1c in the groups with type 2 diabetes 
and ACS and T2DM without ACS was not statistically 
different. Besides, patients with and without ACS did 
not have statistical differences in HbA1c level. The 
data of our study can be supported by the results of 
such large projects as the prospective observational 
study of the Verona Diabetes Study, where the main 
independent predictor of death in patients with diabetes 
was not HbA1c level, but glycemic variability [35].
The TC level, despite the increased level in 
both study groups, is not associated with ACS in our 
study. This fact corresponds to the results of many 
other studies that do not show the effectiveness of TC 
reduction to prevent the myocardial infarction risk [36].
In our study, there were no significant differences 
in LDL levels found between study groups. This fact 
contradicts the widely accepted theory of atherogenesis. 
These results can be explained by the limitation of the study 
as a small sample. One explanation is that our study has a 
small sample size; therefore, it is limited in a score. Unlike 
hypercholesterolemia, the manifestation of dyslipidemia 
in the form of a decreased serum HDL is identified as 
a more significant factor associated with the onset of an 
ACS, which is also established in our study [37], [38]. The 
average HDL concentration in the T2DM patients without 
ACS corresponds to the recommended target value, 
while in the T2DM patients with ACS, the average HDL 
level is below the recommended level.
Limitations
This study has potential limitations. The effects 
estimated in these models are based on a cohort study 
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with relatively small sample size. The sample, selected 
for this study, was specifically patients with well-
controlled T2DM, thus the results may not be applicable 
for diabetic patients outside of this designation. Future 
prospective studies suggested to estimate insulin and 
glucagon secretion in a more detailed way.
Conclusion
The results of our study showed that there is a 
trend toward elevated HOMA-IR and decreased level 
of glucagon in diabetic patients with ACS. However, 
this trend does not show significant impact on the 
ACS development probability. HOMA-IR and glucagon 
are possibly present a potential role in cardiovascular 
events in patients with T2DM.
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